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TGFβ signaling is necessary for carcinoma cell invasiveness and
metastasis
Martin Oft*‡, Karl-Heinz Heider† and Hartmut Beug*
Background: Invasive growth of epithelial tumor cells, a major cause of death
from cancer in humans, involves loss of epithelial polarity and dedifferentiation.
Transforming growth factor β (TGFβ) is regarded as a major tumor suppressor
during early tumor development because it inhibits cell-cycle progression and
tumor growth. Many dedifferentiated, late-stage tumors are resistant to growth
inhibition by TGFβ, however, and even secrete TGFβ. In line with this, TGFβ is
involved in angiogenesis, wound healing and epithelial–mesenchymal transition
(EMT) during development. Ha-Ras-transformed mammary epithelial cells
(EpRas) undergo TGFβ-induced EMT maintained via a TGFβ autocrine loop.
Thus, we have analyzed whether signal transduction by the TGFβ receptor
(TGFβR) is required for local tumor cell invasion and metastasis.
Results: A dominant-negative type II TGFβR (TGFβRII-dn) was expressed using
retroviral vectors in EpRas cells and highly metastatic mesenchymal mouse
colon carcinoma cells (CT26). In both cell types, TGFβRII-dn blocked TGFβR
signaling and heavily delayed tumor formation. In EpRas cells, TGFβRII-dn
prevented EMT. In the dedifferentiated mesenchymal CT26 cells, TGFβRII-dn
caused mesenchymal-to-epithelial transition and inhibited their in vitro
invasiveness in several assays. In addition, TGFβRII-dn completely abolished
metastasis formation by CT26 cells. Furthermore, several human carcinoma
lines lost in vitro invasiveness when treated with neutralizing TGFβ antibodies
or soluble receptor variants. Finally, human colon carcinoma cells (hnPCC)
expressing a mutated, non-functional TGFβRII were non-invasive in vitro, a
defect restored by re-expressing wild-type TGFβRII.
Conclusions: Cell-autonomous TGFβ signaling is required for both induction
and maintenance of in vitro invasiveness and metastasis during late-stage
tumorigenesis. TGFβRII therefore represents a potential target for therapeutical
intervention in human tumorigenesis.
Background
Epithelial tumors (carcinomas) comprise more than 80% of
the tumors occurring in man and arise through a multistep
process, as best exemplified in human colon cancer [1]
and mouse skin tumor progression [2]. During this
process, epithelial polarity is gradually lost, organ structure
is disrupted and epithelial cells dedifferentiate. Progres-
sion to metastatic carcinomas requires additional changes,
such as proteolytic degradation of the basement mem-
brane, conversion from a sessile to a migratory phenotype,
survival in the blood stream and formation of metastases at
distant sites [3].
Members of the transforming growth factor β (TGFβ)
superfamily are important regulators of embryonic devel-
opment, controlling determination of cell fate during
embryogenesis and inducing mesoderm formation and
epithelial-to-mesenchymal transition (EMT) [4,5]. TGFβs
are also important as key regulators in carcinogenesis [6,7].
Widely diverse functions in tumor development are
ascribed to TGFβ, its receptor (TGFβR) and to signal
transduction intermediates (SMADs) activated by TGFβ
signalling [8]. TGFβ negatively regulates cell-cycle pro-
gression in epithelial cells, involving Cdk inhibitors such
as p27 and p15INK4B [9,10]. Tumor cell growth at early
stages is inhibited by TGFβ [6], suggesting that TGFβ
and its downstream effectors act as tumor suppressors.
TGFβR and components of the TGFβ signal transduction
pathway (Smad4/DPC4) are mutated in certain human
tumors [11–13] and most human tumor cells are resistant
to TGFβ-induced growth inhibition [14].
Positive effects of TGFβ-induced signals are of similar
importance for TGFβ function in carcinogenesis. Many
late-stage or even metastatic human tumors overexpress
TGFβ [15–18]. Resistance to TGFβ-mediated growth
inhibition may arise from mutations of proteins within
the TGFβ signalling pathway, but can also involve
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downstream cell-cycle regulators such as p15INK4b,
p16INK4a or Cdc25A [10,19,20]. Mutations in the genes
encoding TGFβR type II (TGFβRII) or DPC4 are
restricted to specific tumor types [11–13]. Furthermore,
chemically induced tumors in heterozygous TGFβ1+/–
mice do not lose the second copy of the TGFβ1 gene
[21]. Finally, TGFβ actively promotes angiogenesis and
endothelial cell spreading, wound healing and immuno-
suppression [22–24], in accord with a positive role for
TGFβ family members in carcinogenesis. In line with
this, TGFβ promoted squamous-to-spindle cell transi-
tions in a transgenic mouse model for multistage skin
carcinogenesis [6,7].
Recently, we described a mouse mammary carcinoma
model — Ha-Ras-expressing mammary epithelial cells
(EpRas) — in which TGFβ actively promotes tumor pro-
gression [25]. TGFβ induced fully polarized, non-invasive
epithelial cells to acquire a mesenchymal, spindle cell
phenotype (that is, EMT). The mesenchymal cells
obtained after EMT in vitro or cultivated from tumors
were invasive in several in vitro assays. They displayed
autocrine production of TGFβ, which is required to main-
tain the mesenchymal, spindle-like, invasive cell pheno-
type, as neutralizing antibodies to TGFβ caused reversion
to a polarized, epithelial phenotype. TGFβ production by
the tumor cells and acceleration of EMT by exogenous
TGFβ could also be demonstrated in vivo [25].
These results raised the issue of whether TGFβ secreted
by TGFβ-resistant human tumors may be functionally
important for promoting late-stage tumor progression.
According to the tumor suppressor model, exposure to
TGFβ might select for cells that are incapable of transduc-
ing TGFβ-mediated signals and are thus resistant to
TGFβ-induced growth arrest. This would facilitate the
accumulation of further mutations favoring EMT or squa-
mous-to-spindle cell transitions. Alternatively, continuous
signaling through TGFβ-activated signaling pathways (for
example those caused by an autocrine TGFβ loop) might
be necessary to induce and maintain an invasive tumor
cell phenotype. Furthermore, the TGFβ produced by
human tumors in vivo might just act in a paracrine fashion,
for example on tumor stroma, endothelial cells and cells of
the immune system.
In this paper, we have investigated the possible, cell-
autonomous function of TGFβ during invasion and
metastasis of late-stage epithelial tumor cells. A domi-
nant-negative version of TGFβRII (TGFβRII-dn) was
employed to inhibit TGFβR signaling in EpRas cells and
highly metastatic mouse colon carcinoma cells, which
display a spindle-like, mesenchymal phenotype and are
resistant to TGFβ-mediated growth inhibition (CT26 and
C26 cells). TGFβRII-dn retarded tumor formation by the
epithelial EpRas cells and prevented EMT in vivo. In the
mesenchymal colon carcinoma cells, TGFβRII-dn
induced mesenchymal-to-epithelial transition (MET) and
abolished invasiveness in vitro. In mice, tumor outgrowth
of TGFβRII-dn-expressing CT26 and C26 cells was
retarded or even inhibited and metastatic spreading of
residual tumor cells was completely abolished. These
effects were cell autonomous, as GFP-labeled cells
expressing TGFβRII-dn failed to contribute to primary
tumors or metastases caused by unmodified tumor cells.
Interference with potential autocrine stimulation by TGFβ
in human tumor cells inhibited local invasiveness of several
unrelated human tumor cell lines in vitro. Colon tumors of
the hereditary nonpolyposis colorectal cancer (hnPCC)
group expressing a dominant-negative mutation of
TGFβRII [12] displayed an intrinsically low invasive
potential. The invasiveness of these cells could be restored,
however, by re-expressing a wild-type TGFβRII. Thus, a
major function of TGFβ is to act as a cell-autonomous pro-
moter of late-stage human tumor development.
Results
Inhibition of TGFβ signaling prevents EMT in epithelial
cells and causes MET in mesenchymal spindle tumor cells
EpRas cells are induced to undergo EMT by exogenously
added or stroma-derived TGFβ in vitro and in vivo [25].
We investigated whether inhibition of signal transduction
by TGFβR would interfere with tumor growth and inhibit
EMT in vivo. TGFβ acts by binding to TGFβRII, a
receptor serine/threonine kinase [26]. The ligand–receptor
complex heterodimerizes with TGFβR type I (TGFβRI),
thereby initiating signal transduction [27]. A dominant-
negative, kinase-dead form of TGFβRII (TGFβRII-dn)
[28] was stably expressed in EpRas cells using retroviral
vectors. Cells infected with an empty vector formed
tumors when injected subcutaneously into mice. Upon re-
cultivation, these control tumor cells showed the
expected, mesenchymal-like cell type (Figure 1b) [25]. All
cell lines expressing TGFβRII-dn showed a severely
reduced tumor outgrowth compared to EpRas cells
(Figure 1a) and cells re-cultivated from the small tumor
nodules displayed a polarized, epithelial phenotype
(Figure 1c). Thus, TGFβRII-dn-expressing EpRas tumor
cells are both strongly retarded in tumor outgrowth and
unable to undergo EMT in vivo.
Next, we asked whether TGFβ signaling might also be
required to maintain the already established, invasive
spindle cell phenotype of late-stage tumor cells. The
murine cell line CT26, derived from a chemically induced
colon carcinoma [29], is highly tumorigenic in syngeneic or
nude mice. It also induces blood-borne lung metastases
from the primary tumor site with high incidence. In
culture, CT26 cells display a spindle cell phenotype
(Figure 1d) and fail to express basolateral epithelial
markers such as the junctional proteins E-cadherin and
1244 Current Biology, Vol 8 No 23
ZO-1 (Figure 1f). Expression of TGFβRII-dn in CT26
cells (CKR cells) caused reversion of the mesenchymal,
spindle cell phenotype of CT26 cells towards a cobble-
stone, epitheloid morphology (Figure 1e) and upregula-
tion of junctional cell adhesion molecules such as
E-cadherin and ZO-1 (Figure 1g). These cells formed cell
junctions sufficiently functional to support the formation
of fluid-filled domes (hemicysts), suggesting partial
epithelial polarization (Figure 1e). These results indicate
that interference with TGFβ signaling induces MET in
late-stage, metastatic carcinoma cells. 
TGFβ induces in vitro invasiveness independent of cell-
cycle control
The CT26 colon carcinoma cells and their TGFβRII-dn-
expressing derivatives (CKR cells) are resistant to the
cell-cycle arrest induced by TGFβ in normal epithelial
cells (data not shown). We therefore analyzed whether
TGFβ signaling was still required for in vitro invasiveness
of CT26 cells. Strikingly, the TGFβRII-dn-expressing
CKR cells completely lost their ability to undergo inva-
sive growth in vitro. This result was obtained both in
three-dimensional collagen gels (Figure 2b) and in the
embryonic chicken heart invasiveness assay (ECHA;
Figure 2d). As expected, the parental CT26 cells showed
massive invasive growth in both assays (Figure 2a,c).
These experiments show that CT26 colon cancer cells
retain a functional TGFβ signaling pathway and require
TGFβ-dependent signaling for invasiveness, despite the
fact that they have become completely resistant to TGFβ-
dependent inhibition of cell-cycle progression.
Inhibition of TGFβ signaling retards or abolishes tumor
formation and prevents metastasis in vivo
CT26 cells cause rapidly growing tumors upon subcuta-
neous injection into syngeneic Balb/C mice (Figure 2e) or
nude mice (data not shown). In all 15 CT26 cell clones
stably expressing TGFβRII-dn (CKR cell clones), tumor
growth was delayed or inhibited. Ten CKR clones gave
rise to subcutaneous tumors of varied, but always greatly
reduced, size and growth rate (Figure 2e). Furthermore,
five of the fifteen CKR clones tested did not show any
tumor formation in Balb/C mice, even up to 6 months after
injection. To analyse whether TGFβR signaling was still
intact in CT26 cells, but abolished by TGFβRII-dn
expression, the effect of TGFβ on a TGFβ-responsive pro-
moter element was determined in these cells. In the CT26
control cells, TGFβ strongly stimulated transcription from
a transiently transfected PAI-1 reporter gene construct
(Figure 2f), suggesting intact TGFβR signal transduction
via the SMAD pathway. In contrast, both basal and TGFβ-
induced PAI-1 reporter gene transcription were strongly
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Figure 1
Inhibition of TGFβ signaling interferes with
EMT and tumor growth of EpRas cells and
causes MET in mesenchymal colon
carcinoma cells (CT26). (a–c) TGFβRII-dn
prevents EMT and retards tumor growth in 
v-Ha-Ras-expressing mammary epithelial
cells. (a) Control EpRas cells or EpRas cells
stably expressing a dominant-negative
TGFβRII (TGFβRII-dn) were injected into
nude mice (three mice per clone). Mean
tumor weights obtained four weeks after
injection are shown. Cells re-cultivated from
the control tumors had undergone EMT (b),
whereas cells grown from the tumor nodules
induced by TGFβRII-dn EpRas cells retained
an epithelial phenotype (c). (d–g) Expression
of TGFβRII-dn in spindle-shaped CT26 tumor
cells reverted them towards an epithelial
phenotype. CT26 cells showed a
mesenchymal-like phenotype in phase
micrographs (d) and failed to express the
epithelial markers E-cadherin and ZO-1 (f).
The TGFβRII-dn-expressing CT26 clone
CKR2 regained epitheloid morphology,
formed hemicysts (e) and expressed 
E-cadherin and ZO-1 (g).
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inhibited in all TGFβRII-dn-expressing CKR clones,
often to an extent obtained in CT26 cells transiently trans-
fected with a TGFβRII-dn expression construct
(Figure 2f). The complete (CKR clones 1/2) or partial
(CKR clones 6/10) inhibition of TGFβ-dependent PAI-1
promoter activation correlated closely with the complete or
partial inhibition of in vivo tumor growth in the same
clones (compare Figure 2 parts e,f).
CT26 cells show a high ability to form blood-borne lung
metastases. We therefore analyzed whether the develop-
ment of such metastases in CT26 tumor-bearing animals
would also require signaling by the TGFβ–TGFβR
complex. In a first set of experiments, primary tumors
grown from TGFβRII-dn-expressing CKR cells and CT26
control cells were surgically removed at a given size
(2 cm3). Thus, we avoided any influence of tumor size on
metastasis probability, creating an experimental setting
closely resembling the situation in tumor patients. Tumors
derived from CT26 cells caused lethal lung metastases
three weeks after tumor excision (6 weeks after subcuta-
neous injection of mice with 1×106 cells). All CKR cell
clones — even those that did form primary tumors — com-
pletely failed to form lung metastases after tumor excision,
even after observation times up to 9 months (Table 1).
Finally, we sought to determine whether TGFβ signal
transduction was also required for evasion of the metastatic
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Figure 2
TGFβ signaling in CT26 cells is required for
invasiveness in vitro and tumor outgrowth in
vivo. (a–d) In vitro invasiveness assays. CT26
cells (a,c) showed invasive growth in three-
dimensional collagen type I gels (a) or in the
chicken heart invasiveness assay (ECHA;
cryosections of heart fragments) (c). The
TGFβRII-dn-expressing CT26 clone CKR6
(b,d) failed to show in vitro invasiveness in
both assays. (Insets show higher
magnifications.) CH, chicken heart fragment
(the dotted line marks the border of the
fragment). (e) Tumor outgrowth after
subcutaneous injection into nude mice. Tumor
outgrowth from control CT26 cells (circles) is
shown as is the delayed or absent tumor
outgrowth from various CT26 clones (CKR)
expressing TGFβRII-dn (squares). Note that
clones with medium-level TGFβRII-dn
expression (CKR clones 6/10, verified by
inhibition of PAI-1 reporter gene transcription
— see panel f) showed slow tumor growth,
whereas clones with high-level TGFβRII-dn
expression (clones CKR 1/2 — see panel f))
failed to form tumors. (f) PAI-1 reporter gene
expression was measured in CT26 control
cells and in several TGFβRII-dn-expressing
CT26 clones also analyzed for tumor
formation (CKR clones 1–10), both before
and after TGFβ induction. As a positive
control, CT26 cells were co-transfected with
a TGFβRII-dn expression construct. Note that
suppression of PAI-1 reporter gene
expression and inhibition of tumor formation
correlates clearly in the clones analyzed — see
(e). Mean values and standard deviations
(error bars) are shown from at least three
independent determinations. 
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cells from blood vessels at presumptive metastasis sites
(extravasation). Different numbers of TGFβRII-dn-
expressing CKR cells and control CT26 cells were injected
intravenously into nude mice and syngeneic Balb/C mice.
In control CT26 cells, this caused lethal lung metastasis in
all animals within 2–4 weeks (Table 1), whereas most
(95%) of the CKR clones failed to form any metastases.
The remaining 5% of the CKR clones, which did form
metastases with a significant delay, had all regained
responsiveness to TGFβ with respect to transient PAI-1
gene transcription upon recultivation from the metastases.
Thus, these cells had probably been selected for loss of
TGFβRII-dn expression in vivo.
These experiments show that invasiveness in vitro, rapid
tumor formation in mice (requiring local tumor cell
spreading) and formation of blood-borne lung metastases
require a functional TGFβ–TGFβR complex and active
TGFβ-mediated signal transduction.
Cell-autonomous TGFβ signaling is required for
contribution of tumor cells to tumors and metastases
In the previous experiments, cell lines stably expressing
TGFβRII-dn were used that might have undergone alter-
ations caused by prolonged cultivation, cloning and drug
selection for TGFβRII-dn expression. More importantly,
our experiments did not rule out the possibility that inhi-
bition of TGFβR signaling mainly affects stroma–tumor
cell interactions and interferes with the recruitment of the
required tumor stroma by the injected cells. To address
these issues, we co-expressed TGFβRII-dn and the green
fluorescent protein (GFP) in a second mouse colon cancer
cell line (C26), which metastasizes even more aggressively
than CT26 cells [30]. The C26 cells were infected with a
retrovirus expressing TGFβRII-dn and GFP. Control cells
were infected with a retrovirus expressing GFP only. Two
days after viral infection, the unselected C26 cell popula-
tions contained about 5% GFP-positive cells.
The usefulness and efficiency of GFP as a marker for
TGFβRII-dn expression and prevention of TGFβ signal-
ing was first tested in vitro. C26 cells infected with the
GFP control vector exhibited a highly invasive, spindle-
like cell phenotype in collagen gels, regardless of whether
they did or did not express GFP (Figure 3a,c). In contrast,
C26 cells expressing both GFP and TGFβRII-dn formed
tight nodules unable to invade the collagen gel even when
surrounded by invasive, uninfected C26 cells
(Figure 3b,d).
This technique also allowed us to determine the fate of
GFP-positive, TGFβRII-dn-expressing or control cells in
an environment of unmodified tumor cells, both in subcu-
taneous tumors and lung metastases induced by these cell
preparations. Upon subcutaneous injection into syngeneic
mice, both cell preparations invariably gave rise to primary
tumors and large lung metastases within 3 weeks in all
animals, but only the control cells expressing GFP alone
contributed significantly to primary tumors or lung metas-
tases (Figure 3e,g, arrowheads). In contrast, C26 cells
expressing both TGFβRII-dn and GFP were unde-
tectable in both primary tumors and metastases
(Figure 3f,h). Thus, interference with TGFβ-induced
signal transduction confers a strong, cell-autonomous
growth/migration disadvantage for C26 colon carcinoma
cells in vivo.
Finally, we asked whether freshly infected, TGFβRII-dn-
expressing or control cells were able to form blood-borne
metastases after intravenous injection in the absence of
any primary tumor. C26 cells infected with GFP alone or
both TGFβRII-dn and GFP were sorted by fluorescence-
activated cell sorting (FACS) for GFP fluorescence, and
1 × 106 cells were subsequently injected into nude mice
(Figure 4). The C26 cells infected with GFP alone gave
rise to heavily enlarged lungs due to innumerable metasta-
sis nodules within 4 days after injection (Figure 4a). In
contrast, no lung metastases were detected even micro-
scopically after injection of 1×106 FACS-sorted C26 cells
with both TGFβRII-dn and GFP, even after prolonged
observation (Figure 4b).
In conclusion, maintenance of EMT, local tumor cell
spreading and blood-borne transfer of metastatic cells to
distant organs required sustained, cell-autonomous TGFβ
signaling in two murine tumor/metastasis models.
TGFβRII-dn expression strongly interfered with these
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Table 1
Formation of lung metastases is dependent on TGFβRII signal
transduction.
(a) Metastasis formation from subcutaneous tumors after tumor
excision
CT26 CT26 + TGFβRII-dn
Lethal lung metastasis 100% (6) 0% (18)
Survival time*/observation time† (days) 24* 266†
(b) Lung metastasis from intravenously injected tumor cells
Number of
injected cells CT26 CT26 + TGFβRII-dn
Lethal lung metastasis 100% (12) 8.3% (24)
Delay (days) 5 × 104 14 (12) n.a. (6)
5 × 103 22 (18) 65, n = 2 (18)
(a) Metastasis formation of CT26 and CKR (CT26 cells expressing
TGFβRII-dn) cells after surgical removal of primary tumor. Numbers of
injected animals are given in brackets. *The maximum survival time or
†observation time after excision of the primary tumor is given.
(b) Metastasis formation of intravenously injected CT26 and CKR
cells. Numbers of injected animals are given in brackets; n.a., not
analyzed (no animals died from metastasis); n = 2, 2 out of 18 animals
died from metastases.
processes, establishing it as a potential drug target for
therapeutical intervention with carcinogenesis.
TGFβ-induced signal transduction is important for late
stages of human carcinogenesis
To address the issue of whether EMT is a significant
event in human carcinogenesis and whether human
tumors require TGFβ-dependent signal transduction for
EMT and invasive cell behavior, two approaches were fol-
lowed. Firstly, primary human tumor samples were histo-
chemically stained for EMT-specific markers as well as
TGFβ production. Secondly, invasive human tumor cell
lines were tested for their dependence on autocrine
TGFβ secretion for matrix invasion in vitro.
Occurrences of EMT and spindle cell carcinomas are con-
sidered to be rare events in human carcinogenesis. Studies
using markers for EMT applicable to fixed tumor material
(such as co-expression of the mesenchymal marker
vimentin with epithelial markers such as basal cytoker-
atins [25]) are largely missing, however. Consecutive serial
sections from 31 renal carcinomas and 65 mammary carci-
nomas of different histopathological types were histo-
chemically stained for vimentin and basal cytokeratins.
Co-staining of vimentin and cytokeratins in a significant
fraction of the tumor cells was seen in 74% of the renal
carcinomas and 25–30% of the mammary carcinomas
(Table 2). A clear increase in the frequency of EMT
(65%) was seen in the few (five) completely dedifferenti-
ated mammary tumors analyzed. All mammary tumors
tested (65) were positive for expression of TGFβ, both by
histochemical analysis using antibodies detecting TGFβ
1, 2 and 3 and by in situ hybridization and reverse tran-
scription–PCR (Table 2). In most tumors, TGFβ expres-
sion was restricted to the actual tumor cells and was low or
absent in the tumor stroma (Table 2 and data not shown).
These results indicate that EMT might be a more fre-
quent event in human tumors than previously thought. 
We then tried to interfere with the potential autocrine
TGFβ stimulation of three unrelated human carcinoma
lines that showed in vitro invasiveness in collagen gels.
Exposure of the nasopharyngeal carcinoma KB
(Figure 5a,b), the kidney carcinoma MZ-1795
(Figure 5c,d) and the mammary carcinoma T47D (data not
shown) cell lines to neutralizing anti-TGFβ antibody or
the soluble, extracellular domain of TGFβRII (data not
shown) inhibited invasive growth in the collagen gels
(Figure 5b,d). Untreated control cells, however, showed
massive, invasive growth under the same conditions
(Figure 5a,c).
Invasiveness is impaired in human colon tumors (hnPCC)
bearing TGFβRII mutations
In certain gastric cancers and hnPCC, both alleles of
TGFβRII are frequently inactivated and even rendered
dominant-negative by mutation ([12], see Discussion). In
addition, overexpression of wild-type TGFβR in respec-
tive tumor cell lines rendered them unable to form tumors
[31]. These data, establishing the TGFβRII gene as a
tumor suppressor gene, seemed at first sight incompatible
with our idea that signal transduction through TGFβR
was required for tumor progression. To test whether the
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Figure 3
Cell-autonomous TGFβ signaling is required for in vitro invasiveness,
tumor growth and metastasis formation. C26 cells were infected with
retroviruses encoding (a,c,e,g) GFP alone or (b,d,f,h) GFP plus
TGFβRII-dn. Cell populations containing 5–10% GFP-positive cells
were then used in the various assays (in the diagrams at the top of the
figure, GFP-positive cells are colored green). (a–d) Invasion properties
in three-dimensional collagen type I gels, analyzed 7 days after
seeding. In GFP-only C26 cell populations, both GFP-positive and
GFP-negative cells show invasive growth (a,c). In the TGFβRII-dn plus
GFP C26 cells, GFP-positive cells form tight clumps, whereas GFP-
negative cells invade the gel (b,d). (e–h) Epifluorescence of unstained
cryosections revealed the contribution of GFP-positive cells to tumors
(e,f) and metastases (g,h; the border of metastases is marked by the
dashed line) after subcutaneous injection of both cell populations into
mice. Note the significant contribution of GFP-only C26 cells (some of
the GFP-positive cells are marked by arrowheads) to tumors (e) and
metastases (g). In contrast, no detectable contribution was seen of
TGFβRII-dn plus GFP C26 cells to tumors (f) and metastases (h).
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constitutive inactivation of TGFβRII in these cell lines
resulted in a less invasive tumor phenotype, we analyzed
the hnPCC-derived colon cancer cell lines DLD1
(Figure 5e) and HCT116 (data not shown) in in vitro
matrix invasion assays. The invasive potential of both
hnPCC-derived cell lines was very low and comparable to
invasive human tumor cell lines after TGFβ neutraliza-
tion. These low invasive properties in vitro were mirrored
by a slow tumor growth and very inefficient metastasis for-
mation in vivo (data not shown). We then restored TGFβ
signaling in DLD1 cells by expressing a wild-type copy of
TGFβRII driven by a Zn2+-inducible metallothionine pro-
moter. Expression of low levels of TGFβRII in the
absence of Zn2+ was sufficient to restore TGFβ-inducible
stimulation of a PAI-1 reporter construct (data not shown),
proving that TGFβ-dependent signal transduction was
intact under these conditions. When analyzed for their
invasive properties, these DLD1 cells expressing low
levels of wild-type TGFβRII showed a drastically
enhanced in vitro invasiveness as compared to the parental
cells (Figure 5f). In contrast, Zn2+ treatment of the same
cells resulted in high-level TGFβRII expression and ren-
dered the cells strongly susceptible to TGFβ-induced
growth arrest and apoptosis (data not shown).
In conclusion, our data suggest that TGFβ produced by
human tumor cells induces and maintains tumor cell inva-
siveness in an autocrine, cell-autonomous fashion. Human
tumor cells constitutively mutated in their TGFβRs show
impaired invasiveness, which is restored by re-expression
of TGFβRII.
Discussion
Late-stage events in carcinogenesis require cell-
autonomous TGFβ signaling
The major finding in this paper is that inhibition of TGFβ
signaling by various means can revert mesenchymal, inva-
sive tumor cells to non-invasive, sometimes even epithe-
lial, cells. Expression of TGFβRII-dn abolishes tumor cell
growth and invasiveness in vitro and in vivo even when the
modified cells are surrounded by unmodified, actively
growing and metastasizing tumor cells. This suggests that
the contribution of TGFβ signaling to invasion is a cell-
autonomous process, the simplest mechanism being an
autocrine loop involving TGFβ and TGFβR.
Results from ourselves and others suggest a role for
TGFβ signaling in the progression of tumors to late
stages. Particularly good examples are keratinocyte
tumors and prostrate cancers. In Ras-induced murine
skin cancer, expression of TGFβ in transgenic mice
under the control of a keratin promoter inhibits forma-
tion of benign papillomas, but increases progression of
the residual benign tumors to spindle cell carcinomas,
which also upregulate TGFβ-3 expression [6]. Also,
expression of TGFβRII-dn in a squamous carcinoma cell
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Figure 4
TGFβ signaling is required for metastasis in
the absence of a primary tumor. C26 cell
populations expressing (a) GFP alone or 
(b) GFP plus TGFβRII-dn were sorted by
FACS for GFP expression (GFP-positive cells
are colored green). Sorted cells (1 × 106)
from each preparation were intravenously
injected into mice. Histological sections from
lungs processed 4 days after cell injection are
shown. Note numerous large metastases in
(a) (some nodules are indicated by
arrowheads) and a histologically normal lung
in (b). Insets show higher magnifications.
(a)
Infect CT26 cells
Sort by FACS for GFP
Control GFP vector TGFβRII-dn + GFP
(b)
Inject into mice
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line prevented the spontaneous progression of these cells
to a spindle cell phenotype [7]. In a murine prostate
cancer model and in human prostate tumors, early
benign tumors expressed TGFβ mainly in the tumor
stroma and extracellular space around the epithelial
tumor cells. In contrast, late-stage carcinoma cells pro-
duced TGFβ intracellularly [32,33]. In addition, cell
lines from primary tumors retained TGFβ-dependent
growth inhibition, whereas respective lines from pro-
gressed, metastatic tumors had lost this property [34].
Intracellular TGFβ expression was also seen in our own
studies using renal cancers and late-stage, invasive breast
cancers (Table 2). Many of these tumors also co-expressed
vimentin and cytokeratin, suggesting that they had under-
gone EMT (Table 2). Thus, EMT, as diagnosed by
vimentin/cytokeratin co-expression, seems to be a rather
frequent event in human carcinomas. A possible reason
that this was not described earlier is that histological crite-
ria do not discriminate between mesenchymal tumor
stroma and epithelial cells after EMT. Thus, carcinoma
cells after EMT may often have been misdiagnosed as
tumor stroma.
Tumor suppressor mutations in components of the TGFβ
signaling pathway are rare events in human tumors
Currently, TGFβ itself, its receptors and the TGFβR-acti-
vated signal transducers Smad2 and Smad4/DPC4 are
mainly thought to function as tumor suppressors [12,13,21].
1250 Current Biology, Vol 8 No 23
Table 2
Expression of EMT markers and TGFβ in human tumors.
(a) Co-expression of vimentin and basal cytokeratins
Tumor type Number of Number of
tumors tumors
analyzed co-expressing
vimentin/cytokeratin*
Renal cell carcinomas 31 23/31 (74%)
Mammary tumors 65 19/65 (29%)
Fibroadenoma 3 2/3 (66%)
Invasive ductal carcinoma 34 8/34 (24%)
Invasive lobular carcinoma 26 7/26 (27%)
Invasive ductal–lobular carcinoma 1 1/1
Unknown 1 1/1
(b) Expression of TGFβ 1/2
Tumor type Antibody In situ
staining† hybridization‡
Mammary tumors
Fibroadenoma 4/4 (100%)
Invasive ductal carcinoma 33/33 (100%) 13/13 (100%)
Invasive lobular carcinoma 23/23 (100%) 9/9 (100%)
Invasive ductal–lobular carcinoma 1/1 (100%)
*Histochemical staining of tumor sections with vimentin and cytokeratin
antibodies [25] using consecutive sections. Colocalization of
cytokeratin and vimentin was verified by double immunofluorescence
staining of the same sections with vimentin and cytokeratin antibodies.
†Histochemical staining with anti-TGFβ1 and anti-TGFβ2 antibodies
(Santa Cruz); confirmed with double immunofluorescence using
cytokeratin and TGFβ antibodies. ‡In situ hybridization was performed
as described in [25], using a probe (pmTGFβ) detecting TGFβ 1, 2
and 3. Adjacent serial sections stained by immunohistochemistry
confirmed the result in all cases. Two additional analyses were
performed. First, reverse transcription–PCR on invasive ductal and
invasive lobular carcinomas using primers specific for human TGFβ1:
11 of the cases that were positive with antibody also yielded the
expected reaction product. Second, expression of TGFβ in tumor
stroma: the stroma was weakly stained by antibody in 10/22 cases
where tumor cells stained clearly positive. The stroma was negative in
the remaining 12 cases. From a similar analysis by in situ hybridization:
3/22 cases showed weak staining in the stroma.
Figure 5
TGFβ-dependent invasive properties in vitro of human epithelial tumor
cell lines containing or lacking an intact TGFβRII. (a–d) Invasive human
carcinoma cells rendered non-invasive by interference with TGFβ
signaling. Cells from the nasopharyngeal carcinoma line KB (a,b) and
the kidney carcinoma line MZ-1795 (c,d) were cultivated in serum-
containing collagen gels in the presence of high levels of control
antisera (a,c) or of TGFβ-neutralizing antibody [25] (b,d). Note
inhibition of invasive growth by neutralizing anti-TGFβ antibody. Similar
results were obtained with the T47D mammary carcinoma cell line and
employing a soluble extracellular fragment of TGFβRII (data not
shown). (e,f) Human colon carcinoma cells mutated in the TGFβRII
gene are non-invasive in vitro, a defect restored by exogenous wild-
type TGFβRII. When seeded into collagen gels under identical
conditions to those in (a,c), cells from the hnPCC colon cancer cell
lines DLD1 (e) or HCT116 (data not shown) failed to invade the
collagen gel. DLD1 cells expressing an exogenous wild-type TGFβRII
at low levels regained the ability to invade the collagen gel (f).
(a)
(b)
(c)
(d)
(e)
(f)
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Heterozygous deletion of TGFβ1 in mice leads to reduc-
tion of in vivo TGFβ levels and enhanced susceptibility to
chemical carcinogenesis [21]. The second copy of TGFβ1
is not lost during tumor progression [21], however, suggest-
ing that TGFβ may also have positive functions (such as
stimulation of invasiveness) in these tumors.
TGFβRII is inactivated in certain gastric cancers and in
hnPCC occurring in families with genetic defects in DNA
repair (replication error, RER) [12]. In sporadic colon car-
cinomas [35] or even in lung cancers observed in patients
with RER [36], no mutations in TGFβRII are observed.
Thus, the function of TGFβR as a tumor suppressor is
restricted to very specific tumor types [12,36]. As the RER
defect pre-exists in the hnPCC patients and is responsible
for the TGFβRII mutations, loss of TGFβRII function
may be an early event in hnPCC. This would prevent
selection for mutations specifically inactivating cell-cycle
effectors downstream of TGFβ signaling which would
allow TGFβ signaling to remain intact in the majority of
invasive carcinoma cells.
Likewise, loss or mutation of Smad4/DPC4 mainly occurs
in pancreatic cancer, but is infrequent or not found at all in
other tumor types [11,13,37–42]. This implies that loss-of-
function mutations in the TGFβR signaling pathway, ren-
dering the tumor cell insensitive to TGFβ-induced growth
arrest, may sometimes occur as an early event in specific
tumor types, but does not argue against the concept pro-
posed here, that late events in carcinogenesis are depen-
dent on a functional TGFβ signal transduction pathway.
Conclusions
In most human tumors, cells first become resistant to
TGFβ-mediated cell-cycle inhibition/apoptosis and later
undergo progression towards invasiveness and metastasis
[1]. In this paper, we have shown that signal transduc-
tion by TGFβ receptors is required for induction and
maintenance of EMT and in vitro invasiveness in several
unrelated human and murine epithelial tumor cell lines.
Cell-autonomous TGFβ signaling is similarly required
for induction and maintenance of rapid tumor growth
and metastasis in mice. Interference with TGFβ signal
transduction reverts highly metastatic, mesenchymal
tumor cells to non-invasive ones and reverts EMT,
inducing formation of epithelial cells from tumor cells
with mesenchymal properties.
Our data raise the concept that cell-autonomous signaling
via TGFβ, typically through an autocrine loop, is
required for tumor cells to both invade locally and metas-
tasize to distant organs. TGFβ-induced EMT, a process
that reflects the phenotypic and developmental plasticity
of epithelial cells, occurs during normal palate develop-
ment [15–18,25,43] and constitutes an essential mecha-
nism required for tumor cell invasion and metastasis in
vivo. This suggests that TGFβRII could be a potentially
interesting drug target for therapeutic intervention in
late-stage carcinogenesis.
Materials and methods
Cell culture and retroviral constructs
Cells were cultured as previously described [25]. Briefly, all cell types
were propagated on plastic dishes in DMEM containing 10–20% fetal
bovine serum (FCS). Collagen gel cultures were performed [25] using
a serum-free medium adapted to mammary cell culture (MEGM, Promo-
cell) supplemented with FCS up to 10%, with TGFβ-neutralizing anti-
bodies (mix of Genzyme and R&D antibodies [25]) or with TGFβRII
soluble extracellular fragments (Sigma). To express TGFβRII-dn in cells,
a TGFβRII-K277R cDNA [28] was cloned into the retroviral vector
pBabe-Puro [44] or a corresponding vector containing green fluores-
cent protein (EGFP, Clontech) as a replacement for the puromycin
selection cassette. Cells of the Bosc23 packaging cell line [45] were
transiently transfected with the respective constructs and the target
cells infected with cell-free supernatants from these cells.
Analysis of TGFβ responses
For PAI-1 promoter assays, cells were subjected to lipofectamine-medi-
ated (Gibco) transfection with a construct expressing luciferase under the
control of a triplicated TGFβ-responsive element derived from the PAI-1
promoter (3TPlux [28]). The experimental data were normalized for trans-
fection efficiency to protein content and the activity of a co-transfected
CMV–β-galactosidase control reporter construct. The chicken heart 
fragment invasion assays were performed as described previously [25].
Tumor inductions, tumor removal and metastasis scoring
1×106 of the various tumor cells were subcutaneously injected into
nude mice or immune-competent syngeneic Balb/C mice. Tumors were
surgically removed at a size of 2 cm3 and only animals that were free of
any local recurrence were further analyzed for the induction of metasta-
sis. For quantification and characterization of tumors and metastases,
see [25] and figure legends. All in vivo experiments were performed
using at least three animals per cell type analyzed. Mean values of the
data obtained are depicted.
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